Why Boston Scientific Shares Are Trading Higher Today

  • Boston Scientific Corp BSX generated Q4 revenues of $3.24 billion, in line with the Wall Street estimate.
  • Sales increased 3.7% Y/Y on a reported basis, 8.7% on an operational basis, and 7.1% on an organic basis.
  • The company achieved an adjusted EPS of $0.45, missing the consensus of $0.47.
  • Revenues from MedSurg increased 4.5% to $1.29 billion (8.5% organic), and the Cardiovascular segment generated $2 billion, +6.4% (9.4% organic).
  • Also Read: Boston Scientific Adds 'Novel' Technology Via This Acquisition For Interventional Oncology.
  • The adjusted gross margin remained unchanged at almost 71%, with an adjusted operating income margin of 26%.
  • Outlook: Boston Scientific estimates Q1 FY3 adjusted EPS of $0.42-$0.44 versus the consensus of $0.44
  • The company sees the FY23 adjusted EPS of $1.86-$1.93 versus the Wall Street Estimate of $1.93.
  • The company estimates FY23 sales growth of approximately 5-7% on a reported basis and approximately 6-8% organically.
  • For Q1, Boston Scientific expects sales growth of 3-5% (6-8% organic).
  • Price Action: BSX shares are up 2.55 at $47.43 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!